The global central precocious puberty treatment market encompasses the use of GnRH analogs to manage early puberty, impacting healthcare economics and public health policy. These medications suppress hormones responsible for premature puberty, delaying physical changes and bone maturation to mitigate associated psychological and social challenges. The market's growth and treatment advancements influence healthcare expenditure and resource allocation, prompting considerations for treatment accessibility, affordability, and regulatory policies on a global scale. Stakeholders, including healthcare providers and policymakers, leverage these insights to optimize strategies for addressing pediatric endocrine disorders effectively and sustainably worldwide.
Global Central Precocious Puberty (CPP) Treatment Market is valued at 1,482.52 million in 2021 and is expected to reach USD 2,663.78 million by 2029, with a growing CAGR of 7.60% during the forecast period 2022 to 2029.
To know more, visit https://www.databridgemarketresearch.com/jp/reports/global-central-precocious-puberty-cpp-treatment-market
Below are the Top Central Precocious Puberty (CPP) Treatment Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
AbbVie Inc.
|
AbbVie is known for its strong presence in specialty pharmaceuticals, including treatments for endocrine disorders such as central precocious puberty (CPP). They offer medications such as GnRH analogs, which are pivotal in managing early puberty onset by suppressing hormone production.
|
|
Latin America, South America, North America, Middle East and Africa, and Asia-Pacific Europe
|
In December 2019, AbbVie Inc. went under collaboration with Scripps Research, a company focused on the discovery of new therapeutic options to treat several kinds of diseases belonging to oncology, immunology, neurology, and rare diseases. This collaboration helped the company to enhance its way of drug development to treat various kinds of diseases, which helped it to earn more economic profit.
|
|
2.
|
Endo International plc
|
Endo International focuses on developing and commercializing pharmaceutical products, including treatments for hormonal disorders. They contribute to the CPP treatment market through their portfolio of medications aimed at controlling the timing of puberty in affected children.
|
|
North America, Asia, and Europe
|
In January 2017, Endo International plc initiated a restructuring program to align its business and increase the efficiency of functions such as branded pharmaceutical R&D functions in the U.S. (New York & Pennsylvania). This initiative will increase the R&D activity of its product, thus leading to a rise in revenue generation.
|
|
3.
|
Takeda Pharmaceutical Company Limited
|
Takeda is a global leader in healthcare, offering therapies across various therapeutic areas, including endocrinology. They provide treatments for CPP that help regulate hormonal activity to delay puberty, aligning with their commitment to advancing pediatric health.
|
Prostap - leuproprelin acetate
|
Americas, Middle East and Africa, Asia, and Europe
|
In January 2019, Takeda Pharmaceutical Company Limited acquired Shire plc a company engaged in the manufacturing of medicines for a rare disease such as central precocious puberty. This acquisition strengthened the company’s product portfolio by the addition of new treatment products indicated for the treatment of central precocious puberty.
|
|
4.
|
PT. Daewoong Pharmaceutical
|
Daewoong Pharmaceutical, based in South Korea, plays a significant role in the CPP treatment market by manufacturing and distributing GnRH analogs. Their products contribute to managing early puberty by regulating hormone levels effectively.
|
Luphere Depot
|
North America, Asia-Pacific
|
In May 2020, DAEWOONG PHARMACEUTICAL CO., LTD. announced the expansion of its partnership with Inventage Lab for long-acting injection business such as Luphere Depot. This initiative will help the company to increase its product sale.
|
|
5.
|
Ipsen Pharma
|
Ipsen Pharma specializes in biopharmaceutical solutions with a focus on endocrinology, including treatments for pediatric hormonal disorders such as CPP. Their therapies help delay puberty onset through targeted hormone suppression, supporting optimal management of affected children.
|
|
North America, Asia-Pacific, and Europe
|
In June 2019, Ipsen Pharma extended its strategic partnership with Debiopharm regarding Decapeptyl (triptorelin) for another 15 years. Decapeptyl (triptorelin) is used for the treatment of central precocious puberty in children. This strategic partnership helped the company to boost its revenue by maintaining continued access to products to patients.
|
Conclusion
The central precocious puberty treatment market is shaped significantly by key players such as AbbVie Inc., Endo International plc, Takeda Pharmaceutical Company Limited, PT. Daewoong Pharmaceutical, and Ipsen Pharma. These companies lead in developing and distributing GnRH analogs, crucial for managing early puberty by regulating hormone levels. Their innovations not only advance therapeutic options but also influence healthcare economics and public health policies globally. By addressing the specific needs of pediatric patients with early puberty onset, these companies contribute to enhancing quality of life and ensuring sustainable management of pediatric endocrine disorders on a global scale.
